EASL 2026
27 - 30 May 2026
FGF21 analogues: From pathways to clinical implications
Meeting description
Friday, 29 May 2026
16:15 - 16:17
(CEST)
Welcome & introduction
Mazen Noureddin
16:17 - 16:25
(CEST)
From hidden pathways to clinical impact: FGF21 biology in the liver
Mazen Noureddin, Mary E. Rinella
16:25 - 16:30
(CEST)
Audience Q&A
Mazen Noureddin, Mary E. Rinella
16:30 - 16:38
(CEST)
Spotlighting FGF21 analogues: The evolving management of MASH
Mary E. Rinella, Mazen Noureddin
16:38 - 16:43
(CEST)
Audience Q&A
Mazen Noureddin, Mary E. Rinella
16:43 - 16:45
(CEST)
Summary & close
Mazen Noureddin
Keywords